GRI Bio (GRI) AI Stock Analysis

• Market Cap: $3.87M
• Dividend Yield: N/A
• Average Volume (3M): 121.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: N/A
• EPS Growth: 98.55%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -5.80
• Shares Outstanding: 2,347,272
• 10 Day Avg. Volume: 130,263
• 30 Day Avg. Volume: 121,655
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.48
• Enterprise Value/Market Cap: 0.18
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -700.00
• Enterprise Value/Ebitda: -0.02
• 1Y Price Target: $10.00
• Price Target Upside: 502.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: ―

GRI Bio's stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.

Positive Factors

Clinical Trials

The completion of enrollment in the Phase 2a study for GRI-0621 is a positive step in assessing the treatment for idiopathic pulmonary fibrosis.

Market Potential

GRI Bio's focus on developing treatments for conditions with large market potential, such as Idiopathic Pulmonary Fibrosis and autoimmune disorders, presents significant market opportunities.

Safety Profile

Interim safety data show that GRI-0621 is well-tolerated in the study, indicating a favorable safety profile and reducing risks for upcoming data readouts.

Negative Factors

Clinical Trial Risks

Despite the promising market potential, high risks are associated with clinical trials, which could impact the company's drug development success.

Development Timeline

The expected timing for interim and top-line data from the Phase 2a study may delay potential impacts on the stock, as results are anticipated in Q2 and Q3 2025.

GRI Bio Business Overview & Revenue Model

Company Description

GRI Bio (GRI) is a biotechnology company focused on developing innovative therapies to address unmet medical needs in the field of immunology. The company's core products and services revolve around its proprietary platform technology, which aims to modulate immune system responses to treat chronic inflammatory and fibrotic diseases. GRI Bio operates at the intersection of biotechnology and pharmaceuticals, striving to bring novel therapeutic solutions to market.

How the Company Makes Money

GRI Bio generates revenue through the development and commercialization of its proprietary therapies. The primary revenue streams include licensing agreements with pharmaceutical companies and potential milestone payments and royalties from successful drug candidates developed using their platform technology. Additionally, GRI Bio may engage in strategic partnerships and collaborations with other biotech firms to co-develop and market new therapies. The company's earnings are significantly influenced by its ability to advance drug candidates through clinical trials and secure regulatory approvals, as well as the establishment of lucrative partnerships with larger pharmaceutical entities.

GRI Bio Financial Statement Overview

Summary

GRI Bio shows progress in revenue and equity but faces profitability and cash flow challenges. The high operational costs and cash burn pose risks, despite a strong equity position.

Income Statement

GRI Bio's income statement shows some improvement in revenue from the previous year, with a TTM (Trailing-Twelve-Months) total revenue of $4.91 million, up from $0 in 2022. However, the company continues to face significant challenges in profitability, as indicated by negative net income and EBIT margins. The EBIT margin for the TTM is -103.5%, and the net profit margin is -167%, highlighting ongoing operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reflects a stronger equity position, with stockholders' equity of $56.33 million as of the latest period, a recovery from previous negative equity figures. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage, which could be a positive factor in reducing financial risk. The equity ratio stands at 98.14%, showcasing a strong equity base relative to total assets, albeit with limited asset growth.

Cash Flow

GRI Bio's cash flow statement shows a negative operating cash flow and free cash flow in the TTM, with free cash flow at -$8.61 million. The operating cash flow to net income ratio is 1.05, suggesting the company is burning cash at a rate close to its net losses. Free cash flow growth remains negative, indicating ongoing challenges in generating cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	100.00K
Gross Profit	-1.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-11.28M	-8.23M	-10.90M	-2.51M	-963.00K	-4.71M
Net Income	-11.25M	-8.21M	-13.04M	-3.22M	-1.56M	-4.82M
Balance Sheet
Total Assets	4.04M	5.74M	2.96M	383.00K	8.34M	955.00K
Cash, Cash Equivalents and Short-Term Investments	3.28M	5.03M	1.81M	9.00K	7.51M	109.00K
Total Debt	108.00K	119.00K	14.00K	673.00K	169.00K	336.00K
Total Liabilities	2.84M	1.71M	2.70M	2.01M	2.52M	2.41M
Stockholders Equity	1.21M	4.03M	259.00K	-1.63M	5.82M	-1.45M
Cash Flow
Free Cash Flow	-10.35M	-8.61M	-9.15M	-1.09M	-8.31M	-3.71M
Operating Cash Flow	-10.35M	-8.61M	-9.14M	-1.08M	-8.31M	-3.71M
Investing Cash Flow	0.00	0.00	-8.00K	-3.00K	-3.84M	-2.00K
Financing Cash Flow	11.82M	11.83M	10.95M	1.01M	15.75M	-4.00K

GRI Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.66
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Neutral. The current price of 1.66 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.47, and below the 200-day MA of 7.42, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.18 is Neutral, neither overbought nor oversold. The STOCH value of 89.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GRI.

GRI Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.49B	0.22	-61.87%	2.28%	16.62%	1.08%
GRI	45 Neutral	$3.87M	―	-468.00%	―	―	98.55%
SCPX	39 Underperform	$681.32K	―	-174.06%	―	-10.75%	82.25%
ONCO	33 Underperform	$2.50M	―	-237.69%	―	―	-97.16%
SLRX	30 Underperform	$1.68M	―	-300.16%	―	―	79.57%
PCSA	29 Underperform	$5.56M	―	-192.72%	―	―	56.26%